Comparative Pharmacology
Head-to-head clinical analysis: REMICADE versus YUSIMRY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REMICADE versus YUSIMRY.
REMICADE vs YUSIMRY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Infliximab is a chimeric monoclonal IgG1 antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory cytokine activity by preventing its interaction with p55 and p75 cell surface TNF receptors.
YUSIMRY (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and neutralizes its activity, reducing inflammatory responses.
5 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks thereafter; for rheumatoid arthritis, may increase to 10 mg/kg every 8 weeks if needed.
Subcutaneous: 200 mg every 2 weeks. For patients with body weight ≥100 kg, consider 200 mg every week. IV: 300 mg as a loading dose on day 1, then 200 mg every 2 weeks subcutaneously.
None Documented
None Documented
Terminal elimination half-life is approximately 7.7 to 9.5 days (range 7-12 days). The prolonged half-life supports every-8-week dosing; may be shorter in patients with high tumor burden or immunogenicity.
Terminal elimination half-life ranges from 10 to 20 days (mean ~14 days) in adults; consistent with IgG1 monoclonal antibody clearance. Reduced half-life may be observed in patients with high tumor burden or concomitant methotrexate.
Infliximab is eliminated primarily via the reticuloendothelial system. No significant renal or biliary excretion; less than 0.1% of dose excreted unchanged in urine. Clearance is mainly through proteolytic catabolism.
Elimination occurs via reticuloendothelial system with catabolism into amino acids; no significant renal or biliary excretion of intact adalimumab. Mean renal excretion of adalimumab is <1% of dose as intact monoclonal antibody.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor